α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis
Hager, K., Kenklies, M., McAfoose, J., Engel, J., and Münch, G. (2007) α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis. Journal of Neural Transmission, Supplementa, 72 . pp. 189-193.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1007/978-3-211-7357...
Oxidative stress and neuronal energy depletion are characteristic biochemical hallmarks of Alzheimer’s disease (AD). It is therefore conceivable that pro-energetic and antioxidant drags such as α-lipoic acid might delay the onset or slow down the progression of the disease. In a previous study, 600 mg α-lipoic acid was given daily to nine patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of 12 months. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (the mini mental state exam, MMSE and the Alzheimer’s disease assessment score cognitive subscale, ADAScog). In this report, we have extended the analysis to 43 patients over an observation period of up to 48 months. In patients with mild dementia (ADAScog < 15), the disease progressed extremely slowly (ADAScog: +1.2 points/year, MMSE:-0.6 points/year), in patients with moderate dementia at approximately twice the rate. However, the progression appears dramatically lower than data reported for untreated patients or patients on choline-esterase inhibitors in the second year of long-term studies. Despite the fact that this study was not double-blinded, placebo-controlled and randomized, our data suggest that treatment with α-lipoic acid might be a successful ‘neuroprotective’ therapy option for AD. However, a state-of-the-art phase II trial is needed urgently.
|Item Type:||Article (Refereed Research - C1)|
Volume Supp 72
|Keywords:||Alzheimer's disease; lipoic acid; dementia; neuroprotection; open clinical trial|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1109 Neurosciences > 110999 Neurosciences not elsewhere classified @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920111 Nervous System and Disorders @ 100%|
|Deposited On:||22 Sep 2009 15:31|
|Last Modified:||10 May 2013 00:32|
Last 12 Months: 0
|Citation Counts with External Providers:||Web of Science: 42|
Repository Staff Only: item control page